Acerus Pharmaceuticals Corporation Sustainability Profile
Acerus Pharmaceuticals Corporation, often referred to simply as Acerus, is a Canadian biopharmaceutical company headquartered in Ontario, Canada. Founded in 2006, Acerus focuses on developing innovative therapeutic solutions primarily in the fields of men's health and hormone replacement therapy. The company has made significant strides with its flagship product, Natesto, a unique nasal testosterone replacement therapy that offers a convenient alternative to traditional methods. Acerus is committed to addressing unmet medical needs, positioning itself as a leader in the niche market of hormone therapies. With a strong emphasis on research and development, Acerus continues to expand its portfolio and enhance its market presence, striving to improve the quality of life for patients worldwide.
DitchCarbon Score
How does Acerus Pharmaceuticals Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Acerus Pharmaceuticals Corporation's score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Acerus Pharmaceuticals Corporation's reported carbon emissions
Acerus Pharmaceuticals Corporation, headquartered in Canada, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Acerus may not have established formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. In the context of the pharmaceutical industry, many companies are increasingly adopting science-based targets and sustainability initiatives to address climate change. However, without specific emissions data or commitments, it is unclear how Acerus Pharmaceuticals aligns with these industry trends. As the company moves forward, establishing measurable climate goals could enhance its environmental responsibility and align it with broader industry standards.
How Carbon Intensive is Acerus Pharmaceuticals Corporation's Industry?
How Carbon Intensive is Acerus Pharmaceuticals Corporation's Location?
Acerus Pharmaceuticals Corporation's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Acerus Pharmaceuticals Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
